CSF2 and neoplasm: These findings combined with our current results suggest that it is prudent to consider the possibility of inducing tolerogenic DCs, such as OX40L+ G-BMDCs, by GM-CSF, while developing/optimizing therapeutic tumor DC vaccinations.